Compare Enveric Biosciences Inc (ENVB) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $25.97 (market cap $115.44M). The key difference: ProShares UltraShort Bloomberg Natural Gas ETF is far larger — about 17.3× Enveric Biosciences Inc's market cap, and ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| ENVB | KOLD | |
|---|---|---|
Market Cap | $6.69M | $115.44M |
Volume | 41,141 | 6,626,046 |
Sector | Health | Leveraged / Inverse |
52-Week High | $10.80 | $49.39 |
52-Week Low | $1.27 | $13.58 |
Typical Hold Time | 14 Days | 10 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
KOLD is trading at $24.84, down 5.8% over the past 24 hours amid bearish technical signals. The stock faces strong selling pressure with moving averages indicating a bearish trend and oscillators in neutral territory. Recent news highlights natural gas market volatility driven by record production levels and geopolitical tensions in the Middle East affecting energy commodities.
The outlook remains challenging with technical indicators pointing to continued downward pressure. Investment opportunities may emerge if the stock finds support near current levels, but risks include ongoing natural gas price volatility and geopolitical uncertainties. The bearish technical setup suggests cautious positioning is warranted until clearer fundamental catalysts emerge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
